Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.

Autor:	Tran, P. V., Dellva, M. A., Tollefson, G. D., Wentley, A. L., Beasley Jr, C. M., Beasley, C M Jr
Předmět:	DRUG efficacy ORAL drug administration ANTIPSYCHOTIC agents OLANZAPINE THERAPEUTICS SCHIZOPHRENIA PSYCHOSES SCHIZOAFFECTIVE disorders DRUG therapy for psychoses DRUG therapy for schizophrenia BENZODIAZEPINES CLINICAL trials COMPARATIVE studies LIFE expectancy RESEARCH methodology MEDICAL cooperation RESEARCH STATISTICS SURVIVAL analysis (Biometry) TRANQUILIZING drugs DISEASE relapse EVALUATION research TREATMENT effectiveness BLIND experiment HALOPERIDOL
Zdroj:	British Journal of Psychiatry; Jun98, Vol. 172, p499-505, 7p, 2 Charts, 2 Graphs
Abstrakt:	Background: Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses.Method: Data were from double-blind extensions of acute studies. The subjects met criteria for schizophrenia, schizophreniform disorder or schizoaffective disorder. Subjects had responded to acute therapy (Brief Psychiatric Rating Scale total score decreased > or = 40% from baseline (Studies 1, 2, and 3) or was < or = 18 (Studies 1 and 2)) and were out-patients at their last acute phase visit. Relapse was defined as hospitalisation for psychopathology. Subjects treated with olanzapine in the three studies were pooled to form the olanzapine group and subjects treated with haloperidol were pooled to form the haloperidol group.Results: Olanzapine-treated subjects experienced less relapse (P = 0.034). The Kaplan-Meier estimated one-year risk of relapse was 19.7% with olanzapine and 28% with haloperidol.Conclusion: Olanzapine was superior to haloperidol in the maintenance therapy of schizophrenia and related psychoses.Declaration Of Interest: This work was sponsored by Eli Lilly and Company. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu